Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ATNM |
---|---|---|
09:32 ET | 11152 | 8.2 |
09:34 ET | 100 | 8.1593 |
09:39 ET | 100 | 8.2186 |
09:50 ET | 1550 | 8.34 |
09:54 ET | 1800 | 8.38 |
09:56 ET | 1608 | 8.4 |
09:59 ET | 785 | 8.4 |
10:01 ET | 262 | 8.4297 |
10:06 ET | 100 | 8.4282 |
10:12 ET | 1303 | 8.33 |
10:17 ET | 862 | 8.33 |
10:19 ET | 5138 | 8.27 |
10:21 ET | 500 | 8.27 |
10:24 ET | 600 | 8.2882 |
10:26 ET | 429 | 8.2568 |
10:28 ET | 2507 | 8.24 |
10:33 ET | 6299 | 8.23 |
10:35 ET | 1314 | 8.21 |
10:37 ET | 1110 | 8.2374 |
10:46 ET | 670 | 8.215 |
10:48 ET | 168 | 8.2484 |
10:51 ET | 1000 | 8.1901 |
10:55 ET | 2100 | 8.22 |
10:57 ET | 300 | 8.22 |
11:02 ET | 500 | 8.205 |
11:04 ET | 1900 | 8.2 |
11:08 ET | 200 | 8.25 |
11:09 ET | 1975 | 8.25 |
11:11 ET | 500 | 8.24 |
11:20 ET | 200 | 8.265 |
11:27 ET | 100 | 8.2543 |
11:31 ET | 500 | 8.23 |
11:42 ET | 711 | 8.22 |
11:54 ET | 100 | 8.22 |
11:56 ET | 700 | 8.22 |
11:58 ET | 300 | 8.22 |
12:07 ET | 423 | 8.21 |
12:09 ET | 1200 | 8.2001 |
12:12 ET | 4719 | 8.17 |
12:14 ET | 1455 | 8.1512 |
12:25 ET | 335 | 8.11 |
12:27 ET | 900 | 8.11 |
12:30 ET | 500 | 8.11 |
12:43 ET | 800 | 8.06 |
12:50 ET | 500 | 8.06 |
12:54 ET | 400 | 8.06 |
12:56 ET | 600 | 8.06 |
12:57 ET | 1200 | 8.06 |
01:03 ET | 1700 | 8.06 |
01:10 ET | 361 | 8.08 |
01:12 ET | 3566 | 8.06 |
01:14 ET | 300 | 8.06 |
01:17 ET | 250 | 8.06 |
01:19 ET | 200 | 8.08 |
01:24 ET | 1550 | 8.06 |
01:28 ET | 400 | 8.07 |
01:30 ET | 1872 | 8.07 |
01:32 ET | 400 | 8.07 |
01:33 ET | 300 | 8.085 |
01:35 ET | 1100 | 8.07 |
01:37 ET | 500 | 8.07 |
01:39 ET | 200 | 8.07 |
01:42 ET | 250 | 8.0804 |
01:44 ET | 300 | 8.07 |
01:46 ET | 300 | 8.07 |
01:50 ET | 100 | 8.08 |
01:51 ET | 518 | 8.07 |
01:53 ET | 1942 | 8.12 |
01:55 ET | 100 | 8.1 |
01:57 ET | 100 | 8.105 |
02:06 ET | 2130 | 8.1 |
02:08 ET | 600 | 8.09 |
02:09 ET | 1013 | 8.16 |
02:18 ET | 100 | 8.22 |
02:22 ET | 100 | 8.195 |
02:24 ET | 100 | 8.195 |
02:26 ET | 400 | 8.2 |
02:31 ET | 400 | 8.173 |
02:33 ET | 200 | 8.18 |
02:36 ET | 100 | 8.17 |
02:38 ET | 100 | 8.17 |
02:40 ET | 300 | 8.2 |
02:42 ET | 400 | 8.18 |
02:45 ET | 8950 | 8.25 |
02:47 ET | 200 | 8.265 |
02:51 ET | 3139 | 8.225 |
02:54 ET | 200 | 8.205 |
02:56 ET | 200 | 8.2 |
02:58 ET | 722 | 8.24 |
03:03 ET | 235 | 8.215 |
03:05 ET | 100 | 8.2 |
03:07 ET | 100 | 8.2 |
03:09 ET | 100 | 8.2 |
03:12 ET | 1204 | 8.255 |
03:18 ET | 5248 | 8.285 |
03:20 ET | 3413 | 8.2601 |
03:25 ET | 1448 | 8.25 |
03:27 ET | 1049 | 8.235 |
03:32 ET | 600 | 8.23 |
03:34 ET | 5945 | 8.185 |
03:36 ET | 300 | 8.16 |
03:38 ET | 300 | 8.16 |
03:39 ET | 300 | 8.16 |
03:41 ET | 3896 | 8.16 |
03:43 ET | 400 | 8.17 |
03:45 ET | 100 | 8.16 |
03:48 ET | 600 | 8.16 |
03:50 ET | 1981 | 8.15 |
03:52 ET | 2654 | 8.12 |
03:54 ET | 2404 | 8.15 |
03:56 ET | 891 | 8.13 |
03:57 ET | 2313 | 8.11 |
03:59 ET | 2270 | 8.15 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Actinium Pharmaceuticals Inc | 241.5M | -4.7x | --- |
Acrivon Therapeutics Inc | 233.7M | -2.7x | --- |
Opthea Ltd | 232.2M | -1.1x | --- |
Monte Rosa Therapeutics Inc | 250.7M | -1.6x | --- |
XBiotech Inc | 228.1M | -7.2x | --- |
Candel Therapeutics Inc | 256.4M | -6.9x | --- |
Actinium Pharmaceuticals, Inc. is a late-stage biopharmaceutical company. The Company is engaged in developing targeted radiotherapies to improve survival for people who have failed existing oncology therapies. The Company’s advanced pipeline candidates include Iomab-B (pre-BLA & MAA (EU)) and Actimab-A. Iomab-B is an induction and conditioning agent prior to bone marrow transplant. Actimab-A is a therapeutic agent, have demonstrated potential to extend survival outcomes for people with relapsed and refractory acute myeloid leukemia. The Company focuses on advance Iomab-B for other blood cancers and next generation conditioning candidate Iomab-ACT to improve cell and gene therapy outcomes. The Company holds patent applications including several patents related to the manufacture of the isotope Ac-225 in a cyclotron. Actinium-225 is a potent alpha-particle emitter that has high linear energy transfer capable of killing targeted cancer cells via double-strand breaks in DNA.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $242.7M |
---|---|
Revenue (TTM) | $81.0K |
Shares Outstanding | 29.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.12 |
EPS | $-1.72 |
Book Value | $1.32 |
P/E Ratio | -4.7x |
Price/Sales (TTM) | 2,996.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -61,645.68% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.